| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | The cytoskeletal fraction of rat colon epithelium was used as the immunogen for this Cytokeratin 17 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target |
Overview
Cytokeratin 17 Antibody is a research-use primary antibody intended for detection of CYTOKERATIN in experimental workflows. It is supplied in Purified format. Key antibody attributes include Mouse, Monoclonal (mouse origin), clone E3, isotype Mouse IgG2b, kappa. Applications listed for this product include FACS, IF, WB, IHC-P. Reported/annotated localization context: Cytoplasmic. Species reactivity (as provided): Human, Rat.
Key elements and design rationale
- Target: CYTOKERATIN (Cytokeratin 17) — selectivity and interpretation should be considered in the context of isoforms, post-translational modifications, and related family members when applicable.
- Format: Purified — format can influence background, multiplexing compatibility, and downstream detection strategies.
- Antibody identity: Mouse, Monoclonal (mouse origin), clone E3, isotype Mouse IgG2b, kappa — these attributes help align secondary reagents and controls (e.g., isotype-matched controls) with your assay design.
- Localization: Cytoplasmic — expected subcellular distribution can guide band/structure interpretation and help flag off-target signal.
- Product notes (from provided description): Cytokeratin 17 (CK17, Keratin 17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Cytokeratin 17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to cytokeratin 17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. It is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because cytokeratin 17 antibody marks basal cell differentiation. Cytokeratin 17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. Cytokeratin 17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including cytokeratin 17 antibody. Also important is that cases of triple negative breast carcinoma with expression of keratin 17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually antibody to cytokeratin 17 and MUC1 immunoreactivity represents pancreatobiliary subtype whereas antibody to MUC2 and CDX2 positivity defines intestinal subtype.
Where multiple assay formats are possible, align the antibody format, host/isotype, and listed applications with your detection system and controls to support clear interpretation of signal.
Biological background
In this catalog, CYTOKERATIN is positioned within Oncology & Angiogenesis, Cancer, Tumor research contexts. Localization annotations (e.g., Cytoplasmic) can help contextualize expected signal patterns in imaging and fractionation-based readouts. For authoritative gene/protein nomenclature, domains/isoforms, and curated functional annotations, consult resources such as UniProt, NCBI Gene, and Ensembl.
Research relevance and current trends
- Higher-plex and spatially resolved readouts (e.g., multiplex IF/IHC, spatial omics) are increasing demand for well-characterized primary antibodies with clearly stated host/isotype and labeling strategies.
- Genetic perturbation controls (knockout/knockdown) and orthogonal measurements (e.g., RNA vs protein) are commonly used to strengthen target attribution when interpreting antibody-derived signals.
- Reproducibility initiatives emphasize transparent reporting of antibody identity (clone, host, isotype) and experimental context to improve cross-study comparability.
Common research applications
- FACS: interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform/PTM differences across conditions.
- IF: interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform/PTM differences across conditions.
- WB: interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform/PTM differences across conditions.
- IHC-P: interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform/PTM differences across conditions.
- Typical workflow themes: Western blot validation, IHC on FFPE tissue, IF/ICC localization, Flow cytometry staining, Specificity controls.
- Workflow notes: Validate CYTOKERATIN17 by Western blot in cell/tissue lysates (include controls), Detect CYTOKERATIN17 by IHC in FFPE tissue sections (optimize antigen retrieval + dilution), Detect CYTOKERATIN17 localization by IF/IC…
When comparing conditions, consistent sample processing and appropriate negative/positive controls support interpretation of qualitative localization differences and quantitative abundance changes.
Notes for experimental interpretation
- Isoforms and post-translational modifications may shift apparent molecular weight or epitope accessibility, especially across cell states or treatments.
- Species and tissue context can affect sequence conservation, expression level, and background binding; predicted reactivity should be verified in your sample.
- Control concepts include isotype-matched controls, secondary-only controls (for indirect detection), and genetic/orthogonal controls (e.g., KO/KD, independent antibodies, or RNA measurements) when feasible.
Monoclonal and polyclonal antibodies can differ in epitope recognition breadth and lot-to-lot characteristics; consider clonality and clone information (when provided) alongside your assay requirements. Conjugated formats may simplify detection but can change background and multiplexing behavior compared with unconjugated primaries.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
